Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

3.6K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.6K
Epigenetic Regulation01:46

Epigenetic Regulation

33.2K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Tumor Progression02:07

Tumor Progression

7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer.

International journal of molecular sciences·2026
Same author

A Bayesian framework for longitudinal EHR and genetic discovery.

Nature·2026
Same author

Genetic and transcriptomic determinants of disseminated coccidioidomycosis identify a founder variant in <i>NLRX1</i> and ancestry-specific rare variants in immune response genes.

medRxiv : the preprint server for health sciences·2026
Same author

The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials.

Cancer chemotherapy and pharmacology·2026
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.

The New England journal of medicine·2026

Related Experiment Video

Updated: Dec 14, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Prostate cancer reactivates developmental epigenomic programs during metastatic progression.

Mark M Pomerantz1, Xintao Qiu1, Yanyun Zhu2

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Nature Genetics
|July 22, 2020
PubMed
Summary

Prostate cancer (PCa) progression involves epigenetic changes, particularly in androgen receptor (AR) binding sites. These sites are pre-populated by transcription factors in normal tissue and hijacked during metastasis, revealing new therapeutic targets.

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.6K
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.0K

Related Experiment Videos

Last Updated: Dec 14, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.6K
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

9.0K

Area of Science:

  • * Genomics and epigenomics
  • * Cancer biology
  • * Prostate cancer research

Background:

  • * Epigenetic processes are crucial for prostate cancer (PCa) development and progression.
  • * Prostate cancer cells rely on the androgen receptor (AR), a key transcription factor.
  • * Understanding regulatory element changes during PCa progression is vital.

Purpose of the Study:

  • * To investigate epigenomic alterations during the transition from normal prostate epithelium to localized PCa and metastatic PCa.
  • * To identify the role of transcription factors FOXA1 and HOXB13 in AR site reprogramming.
  • * To discover novel metastasis-specific enhancers and their association with PCa risk.

Main Methods:

  • * Generation and analysis of 268 epigenomic datasets from human prostate tissue specimens.
  • * Comparative analysis of epigenomic landscapes across normal, localized PCa, and metastatic PCa states.
  • * Identification and functional validation of regulatory elements, including enhancers.

Main Results:

  • * Reprogrammed AR binding sites in metastatic PCa are not new but pre-populated by FOXA1 and HOXB13 in normal epithelium.
  • * Metastasis-associated regulatory elements reactivate latent developmental programs involved in prostate organogenesis.
  • * Novel metastasis-specific enhancers at HOXB13, FOXA1, and NKX3-1 were identified and validated.
  • * Prostate lineage-specific regulatory elements correlate with PCa heritability and somatic mutation density.

Conclusions:

  • * Epigenomic analysis provides fundamental insights into prostate cancer progression mechanisms.
  • * Reprogrammed regulatory elements hijack developmental pathways, offering therapeutic targets.
  • * Identifying metastasis-specific enhancers is crucial for understanding PCa spread and risk.